Goldman Sachs Upgrades Danaher, Downgrades Waters | GenomeWeb

NEW YORK (GenomeWeb News) – Goldman Sachs on Monday upgraded shares of Danaher's stock, while it downgraded Waters' shares.

Analyst Isaac Ro upgraded Danaher to a Buy rating from a prior rating of Neutral and raised the 12-month price target on the company's stock to $88 from $75. He also downgraded Waters to a Neutral rating from Buy, and reduced the price target on its stock to $107 from $117.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.